, Volume 32, Issue 3, pp 169–175 | Cite as

Serum C-reactive Protein (CRP) Levels in Cancer Patients are Linked with Tumor Burden and are Reduced by Anti-hypertensive Medication

  • Michael I. Koukourakis
  • Georgia Kambouromiti
  • Dimitra Pitsiava
  • Pelagia Tsousou
  • Maria Tsiarkatsi
  • George Kartalis


High levels of CRP relate with advanced disease and poor prognosis of cancer patients. CRP serum levels were measured in 684 cancer patients who had undergone complete surgery or inoperable patients. Patients with inoperable tumors had significantly higher CRP levels (1.21 ± 2.2 vs. 0.40 ± 0.4 mg/dL; p < 0.0001). No association with gender, diabetes, autoimmune disease, thyroid disease or allergy was noted. Significantly higher CRP levels were noted in operated patients with hypertension (0.55 ± 0.5 vs. 0.35 ± 0.4; p = 0.001), coronary disease (0.73 ± 0.8 vs. 0.39 ± 0.4; p = 0.01) and obesity (0.51 ± 0.5 vs. 0.37 ± 0.4; p = 0.04). On the contrary, analysis in the group of inoperable patients showed that hypertensive patients had significantly lower CRP levels (0.64 ± 1.0 vs. 1.36 ± 2.4; p = 0.008). Although the tumor itself is the main factor defining increased CRP levels in cancer patients, hypertension, coronary disease and obesity are also linked with high CRP levels. Anti-hypertensive drugs appear as potent suppressors of the tumor-induced CRP production.


CRP cancer hypertension coronary disease obesity 



C-reactive protein




  1. 1.
    Tillett, W. S., and T. Francis Jr. 1930. Serological reactions in pneumonia with a nonprotein fraction of pneumococcus. J. Exp. Med. 52:561–571. doi: 10.1084/jem.52.4.561.CrossRefGoogle Scholar
  2. 2.
    Hurlimann, J., G. J. Thorbecke, and G. M. Hochwald. 1966. The liver as the site of C-reactive protein formation. J. Exp. Med. 123:365–378. doi: 10.1084/jem.123.2.365.PubMedCrossRefGoogle Scholar
  3. 3.
    Weinhold, B., A. Bader, V. Poli, and U. Rüther. 1997. Interleukin-6 is necessary, but not sufficient, for induction of the human C-reactive protein gene in vivo. Biochem. J. 325:617–621.PubMedGoogle Scholar
  4. 4.
    Ganapathi, M. K., D. Rzewnicki, D. Samols, S. L. Jiang, and I. Kushner. 1991. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J. Immunol. 147:1261–1265.PubMedGoogle Scholar
  5. 5.
    Marnell, L. L., C. Mold, M. A. Volzer, R. W. Burlingame, and T. W. Du Clos. 1995. C-reactive protein binds to Fc gamma RI in transfected COS cells. J. Immunol. 155:2185–2193.PubMedGoogle Scholar
  6. 6.
    Mold, C., H. Gewurz, and T. W. Du Clos. 1999. Regulation of complement activation by C-reactive protein. Immunopharmacology. 42:23–30. doi: 10.1016/S0162-3109(99)00007-7.PubMedCrossRefGoogle Scholar
  7. 7.
    Robey, F. A., K. D. Jones, T. Tanaka, and T. Y. Liu. 1984. Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein. J. Biol. Chem. 259:7311–7316.PubMedGoogle Scholar
  8. 8.
    Du Clos, T. W., L. T. Zlock, P. S. Hicks, and C. Mold. 1994. Decreased autoantibody levels and enhanced survival of (NZB x NZW) F1 mice treated with C-reactive protein. Clin. Immunol. Immunopathol. 70:22–27. doi: 10.1006/clin.1994.1005.PubMedCrossRefGoogle Scholar
  9. 9.
    Gershov, D., S. Kim, N. Brot, and K. B. Elkon. 2000. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J. Exp. Med. 192:1353–1364. doi: 10.1084/jem.192.9.1353.PubMedCrossRefGoogle Scholar
  10. 10.
    Tsilidis, K. K., C. Branchini, E. Guallar, K. J. Helzlsouer, T. P. Erlinger, and E. A. Platz. 2008. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int. J. Cancer. 123:1133–1140. doi: 10.1002/ijc.23606.PubMedCrossRefGoogle Scholar
  11. 11.
    Siemes, C., L. E. Visser, J. W. Coebergh, T. A. Splinter, J. C. Witteman, A. G. Uitterlinden, A. Hofman, H. A. Pols, and B. H. Stricker. 2006. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J. Clin. Oncol. 24:5216–5222. doi: 10.1200/JCO.2006.07.1381.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee, J. G., B. C. Cho, M. K. Bae, C. Y. Lee, I. K. Park, D. J. Kim, S. V. Ahn, and K. Y. Chung. 2009. Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer. 63:106–110.PubMedCrossRefGoogle Scholar
  13. 13.
    Chiu, H. M., J. T. Lin, T. H. Chen, Y. C. Lee, Y. H. Chiu, J. T. Liang, C. T. Shun, and M. S. Wu. 2008. Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasm in men. Am. J. Gastroenterol. 103:2317–2325. doi: 10.1111/j.1572-0241.2008.01952.x.PubMedCrossRefGoogle Scholar
  14. 14.
    Groblewska, M., B. Mroczko, U. Wereszczyńska-Siemiatkowska, B. Kedra, M. Lukaszewicz, A. Baniukiewicz, and M. Szmitkowski. 2008. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin. Chem. Lab. Med. 46:1423–1428. doi: 10.1515/CCLM.2008.278.PubMedCrossRefGoogle Scholar
  15. 15.
    Nakamura, R. M., E. S. Tucker III, and J. H. Carlson. 1991. Immunoassay in the clinical laboratory. In: John Bernard Henry. Clinical Diagnosis and Management by Laboratory method, 18th ed. New York, Part V, Chapter 34, pp 859–860.Google Scholar
  16. 16.
    Chung, H. W., J. W. Kim, J. H. Lee, S. Y. Song, J. B. Chung, O. H. Kwon, and J. B. Lim. 2009. Comparison of the validity of three biomarkers for gastric cancer screening: carcinoembryonic antigen, pepsinogens, and high sensitive C-reactive protein. J. Clin. Gastroenterol. 43:19–26.CrossRefGoogle Scholar
  17. 17.
    Coombes, R. C., T. J. Powles, J. C. Gazet, H. T. Ford, J. P. Sloane, D. J. Laurence, and A. M. Neville. 1977. Biochemical markers in human breast cancer. Lancet. 1:132–134. doi: 10.1016/S0140-6736(77)91719-6.PubMedCrossRefGoogle Scholar
  18. 18.
    Duffy, S. A., J. M. Taylor, J. E. Terrell, M. Islam, Y. Li, K. E. Fowler, G. T. Wolf, and T. N. Teknos. 2008. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 113:750–757. doi: 10.1002/cncr.23615.PubMedCrossRefGoogle Scholar
  19. 19.
    Liao, W. C., J. T. Lin, C. Y. Wu, S. P. Huang, M. T. Lin, A. S. Wu, Y. J. Huang, and M. S. Wu. 2008. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin. Cancer Res. 14:428–434. doi: 10.1158/1078-0432.CCR-07-1032.PubMedCrossRefGoogle Scholar
  20. 20.
    Macrì, A., A. Versaci, S. Loddo, G. Scuderi, M. Travagliante, G. Trimarchi, D. Teti, and C. Famulari. 2006. Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers. 11:184–193. doi: 10.1080/13547500600565677.PubMedCrossRefGoogle Scholar
  21. 21.
    Taylor, A. W., N. O. Ku, and R. F. Mortensen. 1990. Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-beta. J. Immunol. 145:2507–2513.PubMedGoogle Scholar
  22. 22.
    Yap, S. H., H. J. Moshage, B. P. Hazenberg, H. M. Roelofs, J. Bijzet, P. C. Limburg, L. A. Aarden, and M. H. van Rijswijk. 1991. Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim. Biophys. Acta. 1091:405–408. doi: 10.1016/0167-4889(91)90207-E.PubMedCrossRefGoogle Scholar
  23. 23.
    Sainz, J., E. Pérez, S. Gómez-Lopera, and M. Jurado. 2008. IL1 gene cluster polymorphisms and its haplotypes may predict the risk to develop invasive pulmonary aspergillosis and modulate c-reactive protein level. J. Clin. Immunol. 28:473–485. doi: 10.1007/s10875-008-9197-0.PubMedCrossRefGoogle Scholar
  24. 24.
    Casas, J. P., T. Shah, A. D. Hingorani, J. Danesh, and M. B. Pepys. 2008. C-reactive protein and coronary heart disease: a critical review. J. Intern. Med. 264:295–314. doi: 10.1111/j.1365-2796.2008.02015.x.PubMedCrossRefGoogle Scholar
  25. 25.
    Gortney, J. S., and R. M. Sanders. 2007. Impact of C-reactive protein on treatment of patients with cardiovascular disease. Am. J. Health Syst. Pharm. 64:2009–2016. doi: 10.2146/ajhp060542.PubMedCrossRefGoogle Scholar
  26. 26.
    Magen, E., J. Mishal, J. Paskin, Z. Glick, C. Yosefy, M. Kidon, and M. Schlesinger. 2008. Resistant arterial hypertension is associated with higher blood levels of complement c3 and C-reactive protein. J. Clin. Hypertens. (Greenwich). 10:677–683. doi: 10.1111/j.1751-7176.2008.00002.x.CrossRefGoogle Scholar
  27. 27.
    Li, H., T. Xu, W. Tong, Y. Liu, L. Zhao, and Y. Zhang. 2008. Comparison of cardiovascular risk factors between prehypertension and hypertension in a Mongolian population, inner Mongolia, China. Circ. J. 72:1666–1673. doi: 10.1253/circj.CJ-08-0138.PubMedCrossRefGoogle Scholar
  28. 28.
    Nakou, E., T. D. Filippatos, E. N. Liberopoulos, A. D. Tselepis, D. N. Kiortsis, D. P. Mikhailidis, and M. S. Elisaf. 2008. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin. Pharmacother. 9:1629–1639. doi: 10.1517/14656566.9.10.1629.PubMedCrossRefGoogle Scholar
  29. 29.
    Rajagopalan, S., F. Zannad, A. Radauceanu, R. Glazer, Y. Jia, M. F. Prescott, M. Kariisa, and B. Pitt. 2007. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am. J. Cardiol. 100:222–226. doi: 10.1016/j.amjcard.2007.02.085.PubMedCrossRefGoogle Scholar
  30. 30.
    Palmas, W., S. Ma, B. Psaty, D. C. Goff Jr, C. Darwin, and R. G. Barr. 2007. Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis. Am. J. Hypertens. 20:233–241. doi: 10.1016/j.amjhyper.2006.08.006.PubMedCrossRefGoogle Scholar
  31. 31.
    Schmeisser, A., O. Soehnlein, T. Illmer, H. M. Lorenz, S. Eskafi, O. Roerick, C. Gabler, R. Strasser, W. G. Daniel, and C. D. Garlichs. 2004. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. Biochem. Biophys. Res. Commun. 325:532–540. doi: 10.1016/j.bbrc.2004.10.059.PubMedCrossRefGoogle Scholar
  32. 32.
    Gage, J. R., G. Fonarow, M. Hamilton, M. Widawski, O. Martínez-Maza, and D. L. Vredevoe. 2004. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation. 11:173–180. doi: 10.1159/000076766.PubMedCrossRefGoogle Scholar
  33. 33.
    Yang, J., J. Wang, S. Zhu, X. Chen, H. Wu, D. Yang, and J. Zhang. 2008. C-reactive protein augments hypoxia-induced apoptosis through mitochondrion-dependent pathway in cardiac myocytes. Mol. Cell. Biochem. 310:215–226. doi: 10.1007/s11010-007-9683-3.PubMedCrossRefGoogle Scholar
  34. 34.
    Nabata, A., M. Kuroki, H. Ueba, S. Hashimoto, T. Umemoto, H. Wada, T. Yasu, M. Saito, S. Momomura, and M. Kawakami. 2008. C-reactive protein induces endothelial cell apoptosis and matrix metalloproteinase-9 production in human mononuclear cells: implications for the destabilization of atherosclerotic plaque. Atherosclerosis. 196:129–135. doi: 10.1016/j.atherosclerosis.2007.03.003.PubMedCrossRefGoogle Scholar
  35. 35.
    Yang, J., M. Wezeman, X. Zhang, P. Lin, M. Wang, J. Qian, B. Wan, L. W. Kwak, L. Yu, and Q. Yi. 2007. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell. 12:252–265. doi: 10.1016/j.ccr.2007.08.008.PubMedCrossRefGoogle Scholar
  36. 36.
    Tatokoro, M., K. Saito, Y. Iimura, Y. Fujii, S. Kawakami, and K. Kihara. 2008. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J. Urol. 180:515–519. doi: 10.1016/j.juro.2008.04.025.PubMedCrossRefGoogle Scholar
  37. 37.
    Hefler, L. A., N. Concin, G. Hofstetter, C. Marth, A. Mustea, J. Sehouli, R. Zeillinger, H. Leipold, H. Lass, C. Grimm, C. B. Tempfer, and A. Reinthaller. 2008. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin. Cancer Res. 14:710–714. doi: 10.1158/1078-0432.CCR-07-1044.PubMedCrossRefGoogle Scholar
  38. 38.
    Shiu, Y. C., J. K. Lin, C. J. Huang, J. K. Jiang, L. W. Wang, H. C. Huang, and S. H. Yang. 2008. Is C-reactive protein a prognostic factor of colorectal cancer. Dis. Colon Rectum. 51:443–449. doi: 10.1007/s10350-007-9133-z.PubMedCrossRefGoogle Scholar
  39. 39.
    Sawaki, A., Y. Kanemitsu, N. Mizuno, K. Takahashi, T. Nakamura, T. Ioka, S. Tanaka, A. Nakaizumi, A. A. Salem, R. Ueda, and K. Yamao. 2008. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine. J. Gastroenterol. Hepatol. 23:1292–1297. doi: 10.1111/j.1440-1746.2006.04734.x.PubMedCrossRefGoogle Scholar
  40. 40.
    Beer, T. M., A. S. Lalani, S. Lee, M. Mori, K. M. Eilers, J. G. Curd, W. D. Henner, C. W. Ryan, P. Venner, J. D. Ruether, and K. N. Chi. 2008. ASCENT Investigators. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer. 112:2377–2383. doi: 10.1002/cncr.23461.PubMedCrossRefGoogle Scholar
  41. 41.
    Yoshida, S., K. Saito, F. Koga, M. Yokoyama, Y. Kageyama, H. Masuda, T. Kobayashi, S. Kawakami, and K. Kihara. 2008. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 101:978–981. doi: 10.1111/j.1464-410X.2007.07408.x.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Michael I. Koukourakis
    • 1
  • Georgia Kambouromiti
    • 2
  • Dimitra Pitsiava
    • 3
  • Pelagia Tsousou
    • 1
  • Maria Tsiarkatsi
    • 1
  • George Kartalis
    • 3
  1. 1.Department of Radiotherapy/OncologyUniversity Hospital of Alexandroupolis, Democritus University of ThraceAlexandroupolisGreece
  2. 2.Department of BiochemistryUniversity Hospital of Alexandroupolis, Democritus University of ThraceAlexandroupolisGreece
  3. 3.Department of Internal MedicineUniversity Hospital of Alexandroupolis, Democritus University of ThraceAlexandroupolisGreece

Personalised recommendations